Therapeutic Outlook in DLBCL: Evaluating Treatment Sequencing from Front-line to Relapsed Refractory Disease - Episode 13
Bispecific Antibodies in the Relapsed/Refractory DLBCL Treatment Landscape
A discussion of major challenges in using bispecific antibodies in the relapsed/refractory DLBCL setting, focusing on dosing, safety concerns like CRS, and step-up dosing strategies, along with insights on best practices for community clinics; followed by a review of sequencing bispecific antibodies and CAR T-cell therapies in third-line treatment, informed by recent studies on bispecific/CAR T sequencing
Video content above is prompted by the following:
What are major challenges present when using bispecific antibodies in the RR setting of DLBCL?
- Please discuss challenges associated with dosing as well as safety concerns and discuss how they can be managed.
- Step-up dosing (Dickinson et al. NEJM 2022); CRS (Falchi et al. ASH 2023)
- What insights can you offer community clinics with regards to best practices when using and initiating bispecific antibodies?
ALL: Please share your thoughts on sequencing bispecific antibodies in the 3L setting.
- Review bispecific/CAR T sequencing and share your thoughts: Haydu and Abramson Blood Adv 2024; Haynes et al. ASH 2024